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Highlights: 
 Three strains at various IPP accumulation levels were comparatively analyzed 
 IPP accumulation was linked to decreased cell viability and nutrient uptake 
 IPP-induced pathway “breakage” was characterized using multi-omics data 
 Nucleotide metabolism and ATP synthesis were perturbed by IPP accumulation 
 A nucleotide analog of IPP was identified as a possible contributor to toxicity  
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Abstract  
Isopentenyl pyrophosphate (IPP) toxicity presents a challenge in engineered microbial systems 
since its formation is unavoidable in terpene biosynthesis.  In this work, we develop an 
experimental platform to study IPP toxicity in isoprenol-producing Escherichia coli.  We first 
characterize the physiological response to IPP accumulation, demonstrating that elevated IPP 
levels are linked to growth inhibition, reduced cell viability, and plasmid instability.  We show 
that IPP toxicity selects for pathway “breakage”, using proteomics to identify a reduction in 
phosphomevalonate kinase (PMK) as a probable recovery mechanism.  Next, using multi-omics 
data, we demonstrate that endogenous E. coli metabolism is globally impacted by IPP 
accumulation, which slows nutrient uptake, decreases ATP levels, and perturbs nucleotide 
metabolism.  We also observe the extracellular accumulation of IPP and present preliminary 
evidence that IPP can be transported by E. coli, findings that might be broadly relevant for the 
study of isoprenoid biosynthesis.  Finally, we discover that IPP accumulation leads to the 
formation of ApppI, a nucleotide analog of IPP that may contribute to observed toxicity 
phenotypes.  This comprehensive assessment of IPP stress suggests potential strategies for the 
alleviation of prenyl diphosphate toxicity and highlights possible engineering targets for 
improved IPP flux and high titer isoprenoid production.  
 
Keywords: Isopentenyl pyrophosphate (IPP), IPP toxicity, isoprenol, ApppI, mevalonate 
pathway, multi-omics  
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1. Introduction  
The introduction of heterologous metabolic pathways into naive microbial hosts can 
result in metabolite or product toxicity (Ling et al., 2014).  Although natural metabolic pathways 
have evolved intricate regulation to prevent the buildup of toxic metabolites, heterologous 
pathways, which frequently consist of non-native reactions from different organisms, typically 
lack such sophistication (Chubukov et al., 2016).  Without regulation, imbalances in assembled 
pathways frequently lead to metabolite accumulation and toxicity (Jones et al., 2015).  Typical 
metabolic engineering and synthetic biology workflows for improved pathway expression (Boyle 
and Silver, 2012; Jullesson et al., 2015; Keasling, 2012) may amplify this issue by causing 
massive fluctuations in metabolite concentrations.  Even if a pathway is well-balanced, many 
chemicals targeted for microbial production are toxic at the concentrations that are necessary for 
economical, industrial-scale production (Nicolaou et al., 2010).  The practical importance of 
addressing this toxicity has resulted in numerous studies aimed at interrogating and alleviating 
product toxicity in common industrial hosts such as Escherichia coli and Saccharomyces 
cerevisiae (Mukhopadhyay, 2015).  
Assessment of product or intermediate toxicity is challenging, particularly in an 
engineered host that produces the molecules in vivo.  In engineered microbes harboring 
heterologous pathways, increased metabolic burden (Wu et al., 2016) and unexpected impacts on 
endogenous metabolism make the isolated study of metabolite toxicity difficult.  To avoid this 
complexity, most studies have relied on well-controlled systems where the toxic product is 
exogenously added to the wild-type host and systems analyses are employed to study the stress 
response (Brynildsen and Liao, 2009).  Though multiple studies have successfully used these 
approaches, there are several limitations.  For example, exogenous addition is only successful 
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when the compound of interest crosses the cell membrane through active transport or diffusion 
(Mukhopadhyay, 2015).   While this is not an issue for solvents such as isobutanol (Atsumi et al., 
2010), many toxic intermediates or products contain functional groups that prevent membrane 
transport.  Even if the compound is transported, it is unclear if the stress response associated with 
exogenous addition reflects the response associated with in vivo production.  This is particularly 
true for a wild type host, which likely has different metabolism and overall fitness compared to 
an extensively engineered production strain (Wu et al., 2016).  Finally, exogenous addition can 
introduce unintended artifacts or impurities to the experimental system.  In the case of limonene, 
for instance, extended chemical storage forms hydroperoxide derivatives that are significantly 
more toxic than limonene itself (Chubukov et al., 2015).   
The S. cerevisiae mevalonate pathway for isoprenoid biosynthesis has been heavily 
engineered to produce valuable compounds including the anti-malarial drug artemisinin (Paddon 
and Keasling, 2014) and several candidate biofuels (George et al., 2015a).  Considerable 
progress has been made in the production of isoprenol, a C5 alcohol derived from isopentenyl 
pyrophosphate (IPP), which is one of two universal precursors for isoprenoid compounds 
(George et al., 2015b; Zheng et al., 2013).  In E. coli, the toxicity of both isoprenol (Foo et al., 
2014) and IPP (George et al., 2014) has been suggested to impact cell growth and limit product 
yields.  Although the toxicity of IPP (and its longer chain derivatives GPP and FPP) was 
observed over a decade ago (Martin et al., 2003), a systematic assessment of this stress and its 
impact on host physiology has yet to be conducted.  Metabolic engineering strategies have 
instead focused on avoiding its accumulation, primarily through careful pathway “balancing”, 
improved expression of terminal enzymes, and, most recently, through the assembly of 
alternative pathways (Kang et al, 2016).  Since IPP is a universal precursor for isoprenoid 
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compounds, understanding its mode of toxicity could benefit engineering in a variety of hosts 
and pathway variants.  More broadly, uncovering the mechanism of IPP toxicity could hold 
biological relevance for the study of isoprenoid pathway regulation in a variety of organisms. 
In this work, we developed a three-strain experimental system to study IPP toxicity in 
vivo in isoprenol-producing E. coli.  First, we assessed the impact of IPP accumulation on host 
physiology by measuring growth characteristics, morphology, and viability.  Informed by these 
data, we next collected comprehensive metabolomics and proteomics measurements over an 18-
hour fermentation time course.  We used principal component analysis (PCA) to direct our 
investigation, which linked IPP accumulation to reduced nutrient uptake, a “pause” in 
metabolism, and reduced ATP levels.  Finally, we performed RNA-seq at critical time points 
corresponding to the onset and alleviation of IPP-induced toxicity.  We use these complementary 
data to propose a possible mechanism for IPP toxicity involving the formation of an isoprenyl-
ATP analog, ApppI.   
 
2. Material and Methods 
2.1. Strains and Culture Conditions 
Derivatives of E. coli DH1 WT EV (DH1 harboring pBbA5c and pTrc99A), 3A (DH1 
harboring pJBEI-6829 and pJBEI-6833), and 3Amk (DH1 harboring pJBEI-6829 and pJBEI-
6834) were used in this study.  Overnight cultures were grown in 10 mL of LB media 
supplemented with 30 µM chloramphenicol (Cm30) and 100 µM carbenicillin (Carb100).  Cultures 
were inoculated directly from frozen glycerol stocks and incubating overnight at 37°C.  
Production experiments were carried out in 200 mL of EZ-Rich defined medium (Teknova, 
Hollister, CA) in 1 L non-baffled Erlenmeyer flasks.  EZ-Rich medium was supplemented with 
7 
 
1% w/v glucose as well and Cm30 and Carb100.  Overnight cultures were diluted to an initial OD600 
of 0.1 and incubated at 37°C shaking at 200 rpm until OD600 reached ~0.4-0.6.  When the desired 
OD600 was reached, cultures were induced with IPTG to a final concentration of 500 µM and 
moved to 30°C shaking at 200 rpm.  Re-inoculation experiments to examine pathway breakage 
were conducted by inoculating fresh EZ-Rich medium 1:50 with production culture after 20 
hours. 
 
2.2. Evaluation of IPP Toxicity on Physiology 
To evaluate the effects of IPP buildup on E. coli physiology we measured CFU/mL in 
production curves at 0, 6, 12, and 24 hours post-induction.  Cultures were serially diluted 10-fold 
and then spread on LB agar plates. Colony counts were made after overnight incubation at 37°C.  
We also determined cell viability at 0, 1, 3, 6, 9, and 12 hours post-induction by combining 
nucleic acid staining with flow cytometry.  To measure cell viability, cells were stained with 
nucleic acid-binding dyes SYTO
®
9 and propidium iodide (PI) at a final concentration of 5 µM 
and 20 µM, respectively (Thermo Fisher Scientific, Waltham, MA) for 15 min at room 
temperature according to the manufacturer’s instructions.  Quantitative measurements of 
population viability were done via a BD FACS Aria II, equipped with 488-, 561-, and 633-nm 
solid-state lasers and a forward scatter PMT (BD Biosciences, San Jose, CA).  After staining 
cells were diluted to approximately 10
6
 cells/mL in PBS, and a calibrated suspension of 6 µm 
polystyrene microbeads was added to samples at a density of 1x10
6
 beads/mL to serve as a 
counting standard prior to the data acquisition on the flow cytometer.  A 488-nm (blue) laser was 
used for SYTO
®
9 and PI excitation, and fluorescence emission was detected using a 530/30 
bandpass filter for SYTO
®
 9 fluorescence and a 575/25 bandpass filter for PI fluorescence.  For 
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each sample, 10,000 events were collected at a throughput rate of 1000 events/s, using side 
scatter and forward scatter thresholds of 200.  All flow cytometry data were analyzed with the 
FlowJo package (v X.0.7) (TreeStar Inc., Ashland, OR).  Red fluorescence versus green 
fluorescence scattogram was used to discriminate live and dead populations, and cell 
concentrations were determined from the ratio of cell events to microsphere events in the 
scattogram.  Stained cells were also visualized on a Leica DMC 4000 microscope using a 
Hamamatsu ORCA flash-4.0LT camera using a 63× objective. 
 
2.3. Sampling and Sample Storage 
To sample non-isoprenol metabolites, 1.8 mL of culture was collected in 2 mL microfuge 
tubes at times 0, 0.5, 1, 3, 6, 9, 12, 15, and 18 hours post-induction.  From this sample 0.1 mL 
was used to measure OD600, and 0.2 mL was frozen at -20°C to measure isoprenol.  The 
remaining 1.5 mL were pelleted at 14,000 rpm in tabletop centrifuge. Subsequently 0.25 mL of 
supernatant was frozen at -20°C directly for HPLC analysis of organic acids, and an additional 
0.25 mL was mixed 1:1 in ice-cold MeOH and stored at -20°C for LC-MS investigation of 
extracellular metabolites.  The remaining supernatant was decanted and the pellet was 
resuspended in 0.2 mL of ice-cold MeOH and stored at -20°C to investigate intracellular 
metabolites.  To quantify cellular proteins 5 mL of culture was sampled at the same time points 
as metabolites and centrifuged at 5000 g for 15 minutes.  Samples were then decanted and stored 
at -80°C. RNA sample were taken at 0, 1, and 12 hours after induction.  Volumes corresponding 
to 1E9 CFU/mL were immediately quenched in 2 volumes of RNAlater (Ambion) and left to 
stabilize for 5 minutes at room temperature.  Samples were then pelleted at 5000 g for 15 
minutes, decanted and stored at -80°C.     
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2.4. Isoprenol Quantification 
Isoprenol was quantified by adding 200 µL of ethyl acetate to samples and vortexing 
microfuge tubes at maximum speed on for 15 minutes using a foam adapter.  Samples were then 
centrifuged at 14,000 rpm for 1 minute.  Samples from time points 0, 0.5, 1, 3 had 100 µL of the 
organic (top) phase moved directly into Agilent glass inserts placed into amber GC Vials.  The 
remaining time points had 100 µL of the organic phase diluted into 400 µL of ethyl acetate in 
amber GC vials.  Standard curves for diluted and undiluted samples were run in concert with 
samples from the experiment. Isoprenol concentration was measured by GC-FID (George et al., 
2015a).  
 
2.5. Metabolomics Processing 
Extracellular (supernatant) samples were spun through 3kDa filters (Millipore) at 14,000 
rpm for 1 hour at 4°C and then stored at -20°C.  Intracellular (cell pellet) samples were mixed 
with an equal volume of HPLC grade water (200 µL) and vortexed for 10 seconds.  Samples 
were then pelleted at 14,000 g for 4 minutes at 4°C.  Subsequently 300 µL of supernatant was 
spun through a 3kDa filter (Millipore) for 1 hour at 4°C.  Approximately 250 µL of samples 
passed through the filter and were brought up to 1mL in volume with ice-cold HPLC-grade 
water.  Tubes were then covered in parafilm and had three small holes poked into the top.  
Samples were then flash frozen in liquid nitrogen and placed into metal blocks that had 
previously been stored at -80°C for 1 hour.  Frozen samples were then freeze-dried for 48 hours. 
Freeze dried pellets were then resuspended in 90 µL of mobile phase and metabolites were 
separated via a SeQuant ZIC-pHILIC guard column (20-mm length, 2.1-mm internal 
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diameter, and 5-µm particle size; from EMD Millipore, Billerica, MA, USA), in series with a 
short SeQuant ZIC-pHILIC column (50-mm length, 2.1-mm internal diameter, and 5-µm 
particle size) and a long SeQuant ZIC-pHILIC column (150-mm length, 2.1-mm internal 
diameter, and 5-µm particle size) using an Agilent Technologies 1200 Series Rapid Resolution 
HPLC system (Agilent Technologies, Santa Clara, CA, USA).  Thus, the mobile phase flow path 
was from guard column  short column  long column  time-of-flight mass spectrometer 
(TOF-MS).  Sample injection volume, autosampler tray temperature and column compartment 
were set to 2 µL, 6°C, and 40°C, respectively.  The mobile phase was composed of 10 mM 
ammonium carbonate (Fluka Analytical, Sigma-Aldrich, St. Louis, MO, USA) and 118.4 mM 
ammonium hydroxide (from a 14.8 M ammonium hydroxide solution, EMD Chemicals, 
Billerica, MA, USA) in acetonitrile-water (60.2:39.8, v/v).  Metabolites were eluted isocratically 
via a flow rate of 0.18 mL/min from 0 to 5.4 min, which was increased to 0.27 mL/min from 5.4 
to 5.7 min, and held at this flow rate for an additional 5.4 min, giving a total run time of 11.1 
min.  The HPLC system was coupled to an Agilent Technologies 6210 TOF-MS system.  
Electrospray ionization (ESI) was conducted in the negative ion mode for the detection of [M - 
H]
-
 ions.  Data acquisition and processing were performed by the Agilent MassHunter software 
package.  Visualization and principal component analysis were performed in a Jupyter R 
notebook, “IPP_metabolomics” (Supplemental File S1). 
 
2.6. Proteomic Processing and Analysis 
Protein lysis and precipitation were achieved by using a chloroform-methanol extraction 
as previously described.  Thawed pellets were loosened from 14 mL falcon tubes and transferred 
to 1.5 mL tubes, followed by the addition of 400 µL of methanol, 100 µL of chloroform, and 300 
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µL of water, with vortexing in between each addition.  The samples were centrifuged at 21,000 x 
g for 1 minute for phase separation.  The methanol and water top layer was removed, then 300 
µL of methanol was added and the sample was vortexed.  The samples were centrifuged at 
21,000 x g for 2 minutes to isolate the protein pellet.  The protein pellet was dried for 5 minutes 
at 30ºC in a vacuum concentrator and resuspended in 100 mM ammonium bicarbonate with 20% 
methanol.  The protein concentration was measured using the DC Protein Assay Kit (Bio-Rad, 
Hercules, CA) with bovine serum albumin for the standard curve.  A total of 200 µg of protein 
from each sample was digested with trypsin for shotgun proteomic analysis.  The protein was 
reduced by adding tris 2-(carboxyethyl) phosphine (TCEP) at a final concentration of 5 mM and 
incubating at room temperature for 30 minutes.  The protein was then alkylated by adding 
iodoacetamide at a final concentration of 10 mM and incubating for 30 minutes in the dark.  
Trypsin was added at a ratio of 1:50 trypsin:total protein and the samples were incubated 
overnight at 37ºC. 
As previously described (González Fernández-Niño et al., 2015), peptides were analyzed 
using an Agilent 1290 liquid chromatography system coupled to an Agilent 6550 QTOF mass 
spectrometer (Agilent Technologies, Santa Clara, CA).  Peptide samples (20 µg) were separated 
on an Ascentis Express Peptide ES-C18 column (2.7 µm particle size, 160 Å pore size, 10 cm 
length x 2.1 mm i.d., 60 ºC; Sigma-Aldrich, St. Louis, MO) by using a chromatographic gradient 
(400 µL/min flow rate) with an initial condition of 95% Buffer A (99.9% water, 0.1% formic 
acid) and 5% Buffer B (99.9% acetonitrile, 0.1% formic acid) then increasing linearly to 65% 
Buffer A/35% Buffer B over 30 minutes.  Buffer B was then increased to 80% over 1 minute and 
the held at 80% for 5 minutes followed by ramping back down in 1 minute to 5% Buffer B where 
it was held for 7 minutes to re-equilibrate the column for the next sample.  
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Data were converted to ‘.mgf’ files for analysis with Mascot version 2.3.02 (Matrix Science, 
Boston, MA) with the following parameters: peptide tolerance of ±50 ppm and MS/MS tol- 
erance of ±0.1Da; fixed modifications Carbamidomethyl (C); variable modifications Oxidation 
(M); up to one missed cleavage for trypsin; peptide charge 2+, 3+, and 4+.  Searches were 
performed against an E. coli (strain K12) dataset obtained from UniProt with additional proteins 
associated with the engineered pathway and common contaminant proteins appended to it.  The 
protein and peptide matches from Mascot were refined by using Scaffold version 4.3 (Proteome 
Software Inc.). 
 
2.7. Transcriptomic (RNAseq) Processing and Analysis 
Total RNA was isolated using the Qiagen RNeasy minikit (Qiagen) according to Protocol 
2. Manufacturer’s instructions were followed exactly.  RNA was eluted in one step in 45 µL of 
RNase free water. Total RNA was then treated with TURBO DNase (Ambion) according to 
manufacturer’s instructions.  DNase was then removed with the DNase inactivation reagent and 
removed from the sample at -80°C.  RNAseq was performed by the Vincent J. Coates Genomics 
Sequencing Laboratory at the California Institute for Quantitative Biosciences where rRNA was 
depleted and sequencing was performed on an Illumina 50SR HiSeq 2000 sequencer.  FASTQ 
files were then trimmed and quality filtered using BBDuk, reads were mapped to a DH1 
reference genome via bwa-mem (Li and Durbin, 2009), transcript counts were then quantified 
via featureCounts (Liao et al., 2014), and then differential expression was calculated via DESeq2 
(Love et al., 2014).  The RNAseq data have been deposited in NCBI's Gene Expression Omnibus 
and are accessible through GEO Series accession number GSE102672 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102672).  Functional enrichment 
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analysis using clusterProfiler (Yu et al., 2012) and visualization using Cytoscape via RCy3 
(Shannon et al., 2013) were performed in a Jupyter R notebook, “IPP_transcriptomics” 
(Supplemental File S2). 
 
2.8. Synthesis of ApppI 
Standard sample of ApppI was prepared by Dr. Petri Turhanen’s research team according to the 
procedure described in the reference  (Weisell et al., 2015).   
 
3. Results  
3.1. Developing a platform to selectively assess in vivo IPP toxicity  
The heterologous pathway for isoprenol production in E. coli consists of 8 reactions, 7 of 
which are catalyzed by plasmid-borne genes (Figure 1A).  It was previously demonstrated 
through proteomics analysis that the level of mevalonate kinase (MK) is the primary determinant 
of downstream pathway flux to IPP (George et al., 2014).  We took advantage of this relationship 
to develop an experimental platform to isolate the impact of IPP toxicity from heterologous 
pathway induction (e.g., metabolic burden) and isoprenol production.  This platform consisted of 
three strains (Figure 1B): (1) strain 3A, a balanced, high-yield isoprenol production strain of E. 
coli DH1 harboring two isoprenol pathway plasmids; (2) strain 3Amk, a modified version of 
strain 3A that expresses ~10-fold more MK protein and accumulates IPP; and (3) DH1-EV 
(“empty vectors”, also referred to as WT), E. coli DH1 carrying promoter-less plasmid 
backbones with the same origin and antibiotic markers as those in 3A and 3Amk.   
We first measured optical cell density (OD), intracellular IPP concentration, and 
extracellular isoprenol levels in each strain to ensure the experimental system was functioning as 
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expected (Figure 1C).  Significant growth inhibition was observed in strain 3Amk relative to 
strain 3A following induction, correlating with elevated IPP levels (~370 mM peak concentration 
in strain 3Amk vs. 40 mM in strain 3A).  The growth of an uninduced 3Amk control was not 
inhibited (Supplemental Figure S1).  IPP levels in strain 3Amk peaked at 3 hours post-
induction and subsequently decreased for the remainder of the time course.   The growth rate 
decreased substantially 3 hours post-induction when IPP levels were at their highest, suggesting 
an inverse correlation between IPP levels and growth rate.  By 18 hours, the OD of strain 3Amk 
matched that of strain 3A, although the growth rates observed from 8 to 18 hours were reduced 
relative to strain 3A.  Isoprenol titer was low in strain 3Amk compared to strain 3A: by 18 hours, 
strain 3Amk produced 180 mg/L of isoprenol compared to the ~600 mg/L produced by strain 
3A.  The growth rate of strain 3A was nearly the same as that of the WT despite the 
accumulation of IPP to a concentration of ~40 mM, setting an approximate range of IPP toxicity 
between ~40 mM and ~250 mM (the IPP concentration in strain 3Amk when growth defects 
became apparent).            
 
3.2. IPP accumulation leads to morphological defects, decreased viability, and reduced 
plasmid stability 
We next examined the physiology of each strain to assess the impact of IPP 
accumulation.  To do so, we compared the morphology and viability of strain 3A and 3Amk 
using microscopy, live/dead staining, and CFU counts (Figure 2).  Following pathway induction, 
we observed an increase in dead or metabolically inactive cells in strain 3Amk (Figure 
2A).  Strain 3A remained viable through the time course, with <1% of cells characterized as 
dead, compared to >10% in strain 3Amk.  Microscopy of live/dead stained cells from strain 
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3Amk (Figure 2B) and strain 3A (Figure 2C) showed clear morphological differences.  We 
observed elongated cells in strain 3Amk and a staining phenotype consistent with compromised 
membrane integrity.  We next measured CFUs on solid media to determine if IPP accumulation 
affected the strains’ ability to form viable colonies (Figure 2D).  Surprisingly, CFU counts 
decreased in strain 3Amk from 0 (pre-induction) to 6 hours.  This decrease in CFUs occurred 
despite a ~3-fold increase in OD during the same period.  By 24 hours, CFU counts in strain 
3Amk recovered, matching strain 3A.  To determine if strain 3Amk’s recovery was the result of 
plasmid loss, we compared CFUs recovered on selective media (i.e., LB chloramphenicol to 
select for plasmid 1 and LB carbenicillin for plasmid 2) to those recovered on non-selective 
media.  For strain 3Amk, CFU counts on selective media were ~40% lower than those on non-
selective media at 24 hours, suggestive of partial plasmid loss (Figure 2E).  No such loss was 
observed for strain 3A, where CFUs recovered on selective and non-selective media were 
identical (Figure 2F).  Loss of plasmid 1 was first apparent at 6 hours post-induction, while 
plasmid 2 instability was not observed until 12 hours post-induction.  Intriguingly, all 
populations recovered as IPP levels decreased (i.e., from 6 to 24 hours), implying that plasmid 
loss is not responsible for growth recovery.  Still, the fact that plasmid loss occurred only in 
strain 3Amk suggests that IPP production is detrimental to strain stability, a factor that is 
particularly important for fed-batch fermentation and scale-up.    
Physiological observations indicated that IPP accumulation was associated with 
significant changes in growth rate, cell morphology, cell viability, and plasmid 
stability.  Importantly, E. coli appeared to recover from these perturbations as IPP concentrations 
decreased.  To explore the nature of this recovery, we next collected metabolomics and 
proteomics data to identify potential changes in pathway function.   
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3.3. IPP accumulation is associated with MVA pathway “breakage”  
The production of a toxic intermediate can lead to heterologous pathway “breakage” 
through regulatory feedback or the selection of mutations that attenuate pathway flux and thus 
reduce toxicity (Jones et al., 2015).  In strain 3Amk, the rapid decrease in peak IPP levels and 
associated growth recovery suggested that breakage might have occurred, although the continued 
production of isoprenol implied that the heterologous pathway was at least partially functional.  
To investigate, we measured pathway metabolites and proteins in strains 3A and 3Amk over an 
18-hour time course.   
Pathway proteins were stable except for phosphomevalonate kinase (PMK), which 
unexpectedly decreased in concentration by 8-fold in strain 3Amk from 6 hours to 18 hours post-
induction (Figure 3A).  No such decrease was observed in strain 3A.  Though minor plasmid 
loss occurs in strain 3Amk (Figure 2E), the selective decrease of PMK protein (rather than a 
decline in all pathway proteins) suggested an alternative cause.  Decreased PMK appeared to 
affect pathway flux as levels of Mev-PP, the product of the PMK reaction, declined abruptly 
beginning at 6 hours post-induction (Figure 3B).  IPP levels also fell, though this decrease began 
at 3 hours suggesting multiple mechanisms might be responsible for IPP reduction.  Note that 
HMG-CoA, which was previously shown to be toxic (Kizer et al., 2008), was produced at similar 
levels in both strains (< 1 mM).  Although PMK was the only protein that dynamically declined, 
the absolute levels of PMD and NudB were ~40% lower in strain 3Amk than strain 3A.  Partial 
plasmid loss could contribute to decreased PMD and NudB, though if this was the sole cause 
then similar responses would be expected for all pathway proteins since both plasmids are 
unstable in strain 3Amk.  Decreased levels of LacI and β-Lactamase (Supplemental Figure S2), 
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proteins that were encoded on the same plasmid as NudB and PMD (plasmid 2, Figure 1B), 
were also observed, suggesting that plasmid 2 might be maintained at a lower copy in strain 
3Amk.  Regardless of the explanation, NudB and PMD remained the most abundant pathway 
proteins in strain 3Amk and are unlikely to act as bottlenecks at this concentration (George et al., 
2014).  Consequently, we focused on PMK since its decrease had an obvious impact on pathway 
function.     
Intriguingly, degradation or even complete loss of PMK will still permit isoprenol 
production due to the existence of the “IPP bypass” pathway: the promiscuous activity of PMD 
results in decarboxylation of Mev-P into IP, which is converted into isoprenol through the 
activity of multiple E. coli native phosphatases (Kang et al., 2016).  This “IPP bypass” (Figure 
3C) avoids the complications of IPP formation, provides an outlet for Mev-P (which might 
otherwise be expected to accumulate), and permits the continued production of isoprenol in 
strain 3Amk (Figure 3C).  More importantly, implementation of this alternative pathway may 
contribute to strain 3Amk’s recovery later in the time course.     
We suspected that the minor plasmid loss, reduced viability, and pathway “breakage” 
associated with IPP accumulation would lead to significant strain instability over multiple 
generations.  To investigate, we collected biomass from strain 3A and 3Amk following a 24-hour 
production time course (“primary” cultures) and inoculated fresh cultures (“secondary” cultures) 
that were monitored for growth, intracellular IPP levels, and isoprenol production.  Antibiotic 
selection was maintained in both cultures to ensure that any observed phenotypes were not solely 
due to plasmid loss.  We hypothesized that pathway “breakage” and growth selection would 
result in a secondary 3Amk culture with reduced IPP accumulation and rapid growth.  As 
anticipated, the growth rate of the secondary 3Amk culture was dramatically increased, 
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exceeding even the primary culture of strain 3A (Supplemental Figure S3).  While the primary 
culture predictably accumulated IPP at high concentrations, IPP was at wild-type levels in the 
secondary culture.  Intriguingly, isoprenol was below detection in the secondary 3Amk culture, 
suggesting that PMK is perhaps only one of multiple pathway nodes that are susceptible to 
breakage over time.  There was also evidence of minor pathway breakage in the secondary 3A 
culture, though the continued production of isoprenol showed the pathway was marginally 
functional.  These results underscore the deleterious effect of IPP accumulation on strain stability 
and highlight the need for a more comprehensive assessment of the cell’s metabolic response to 
IPP exposure.       
 
3.4. IPP accumulation is correlated with reduced nutrient uptake, a reduction in ATP 
levels, and a global “pause” in metabolism  
We investigated the impact of IPP accumulation on E. coli metabolism by quantifying 
endogenous metabolites (along with MVA pathway intermediates) in the intracellular (Figure 
4A) and extracellular matrix (Figure 4B).  To reduce the complexity of these data, we used 
principal components analysis (PCA) to identify key drivers of variation between each strain 
(Brunk et al., 2016).  We performed PCA on metabolites found in both the intracellular (Figure 
4C) and extracellular matrix (Figure 4D), respectively.  Please see Supplemental File S1 
(Jupyter R notebook “IPP_metabolomics”) for additional detail and analysis.       
PCA separated strains 3A, 3Amk, and WT into distinct regions based on the intracellular 
data set, particularly in a plot of the first 2 principal components (Figure 4C).  Separation 
between strains was greatest along PC2 (the vertical axis), where pathway metabolites were the 
primary contributors to variation.  IPP explained more of the variance than any other pathway 
19 
 
metabolite, a strong validation of the experimental system.  Separation along PC1 correlated with 
time of measurement (i.e., early time points towards the left of the x-axis, later time points to the 
right), with non-pathway metabolites, particularly amino acids, contributing strongly to variation 
in PC1.   Although intracellular levels of most amino acids decreased over time, rates of 
consumption were significantly decreased in strain 3Amk (Figure 4A).  Metabolites associated 
with response to osmotic stress, including proline and glycine betaine, were elevated in strain 
3Amk (Supplemental Figure S4).  Surprisingly, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate 
(MEcPP), a metabolite in the endogenous 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway 
for isoprenoid biosynthesis, was a significant driver of variation between strain 3A and strain 
3Amk.  In strain 3A, MEcPP accumulated to levels exceeding every other MVA pathway 
intermediate apart from mevalonate by 18 hours.  Other MEP pathway intermediates were also 
detected at elevated levels in strain 3A including MEP and CDP-ME, although these 
concentrations were more than an order of magnitude lower than MEcPP.  Though not identified 
by PCA, the difference in ATP levels between strain 3A and 3Amk was notable (Figure 4E).  
ATP levels in strain 3Amk fell from 5.2 mM pre-induction to 0.8 mM at 3 hours post-induction.  
Adenylate energy charge in strain 3Amk was also reduced relative to 3A and DH1, particularly 
at 1 hour post-induction (Figure 4E).   
Quantifiable amounts of MVA pathway intermediates were detected in the growth 
medium of strains 3A and 3Amk.  While the presence of mevalonate was expected, we were 
surprised at the detection of µM concentrations of mono- and diphosphorylated pathway 
intermediates.  For example, IPP accumulated to ~40 µM at 12 hours post-induction in strain 
3Amk before declining to less than 10 µM by 18 hours.  While this phenomenon was most 
obvious in strain 3Amk, some phosphorylated intermediates such as IP were detected outside the 
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cell in both strains.  Unsurprisingly, PCA of the extracellular data set (Figure 4D) highlighted 
these pathway metabolites as significant drivers of variation.  The strains once again separated 
primarily along PC2, where isoprenol, extracellular pathway intermediates, and acetate were key 
drivers of variation.   MEcPP was also identified as a significant driver of variation: in strain 3A, 
extracellular MEcPP concentrations increased over time, suggesting that this molecule was 
actively exported (Supplemental Figure S5).  Amino acids explained most of the variation in 
PC1, which tracked with time of measurement.  Amino acid uptake rates were reduced in strain 
3Amk relative to strain 3A, particularly during periods of IPP accumulation (i.e., 1 to 9 hours) 
(Figure 4B, Figure 4F).  The impact on glucose uptake by 3Amk was even more striking: 
glucose uptake ceased from 1 to 6 hours post-induction, a timeframe characterized by the highest 
recorded intracellular concentrations of IPP (Figure 4F).  Glucose consumption resumed at a 
rate similar to strain 3A beginning at 12 hours post-induction. 
The reversible reduction in cell growth, viability, and nutrient (e.g., glucose and amino 
acid) uptake suggests that IPP accumulation leads to a “pause” in typical E. coli metabolism.  
Low ATP availability could partially explain this behavior, though it is difficult to determine 
causation since reduced glucose uptake (and subsequently, reduced glycolytic flux) will itself 
decrease ATP levels.  This is clearly seen in the falling ATP levels of DH1 WT from 10 to 18 
hours post-induction (Figure 4E), where glucose uptake rates were reduced (Figure 4F).   
 
3.5. Evidence of IPP uptake in strain 3Amk 
Before continuing our primary analysis, we sought to investigate the unexpected presence 
of extracellular IPP in strain 3Amk.  While cell lysis or membrane leakage could explain its 
release from the cell, we were intrigued by the declining extracellular concentrations after 12 
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hours (Figure 5A).  Specifically, we questioned whether this decline was the result of abiotic 
degradation, enzymatic transformation, or cellular transport.  To clarify this behavior, we 
designed an experiment to evaluate IPP stability in the production media (Figure 5B).  A culture 
of 3Amk was grown to an OD of 0.6, induced with IPTG, and incubated at 30°C using 
conditions identical to the previous metabolomics time course experiment.  At 6 hours post-
induction (a period of increasing extracellular IPP) and 15 hours post-induction (a period of 
decreasing extracellular IPP), supernatant was collected from two 10 mL samples of culture and 
treated with a 0.2 µm filter (filter-sterilized, or “FS” in Figure 5) or a 3kDa molecular weight 
cut-off filter (“MWCO” in Figure 5) to remove residual cells or cells and proteins, 
respectively.  Treated supernatant was incubated with shaking at 30°C and sampled to measure 
IPP concentrations over time.  Supernatant derived from the parent culture (“culture” in Figure 
5) was also sampled to ensure that the previously observed IPP dynamics were reproducible.       
In the supernatant derived from whole cell culture, the previously observed behavior was 
reproduced (i.e., increasing IPP levels up to 12 hours post-induction, decreasing IPP levels from 
12 to 24 hours post-induction).   In both the FS and MWCO treatments, however, levels of IPP 
were unchanged from the time of initial sampling (6 and 15 hours post-induction, Figure 5C and 
Figure 5D, respectively) until the end of the time course.  These results show that IPP is stable in 
the culture media and suggest that cellular uptake is the most likely explanation for declining 
concentrations.  Extracellular IP, which shared a similar profile to IPP and was identified in both 
strains, was also stable in the culture media (Supplemental Figure S6) along with all other 
MVA pathway intermediates.  These data suggest that abiotic degradation plays a minimal role 
in observed metabolite dynamics and offer preliminary evidence that E. coli may be capable of 
transporting phosphorylated MVA pathway intermediates.    
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3.6. IPP accumulation perturbs nucleotide metabolism and induces genes involved in RNA 
processing and modification  
To further characterize the metabolic “pause” and subsequent recovery, we used RNAseq 
to identify differentially expressed genes between engineered strains and the wild-type control at 
time points corresponding with IPP accumulation and reduction in strain 3Amk.  We sampled 
each strain prior to pathway induction (t = 0 hour), at the onset of IPP toxicity in strain 3Amk (t 
= 1 hour), and during growth recovery in strain 3Amk (t = 12 hours).  By comparing the 
transcriptome of all 3 strains, we hoped to isolate the impact of IPP accumulation (differentially 
expressed genes in strain 3Amk only) from the impact of heterologous protein expression and 
metabolic burden (differentially expressed genes in both 3A and 3Amk relative to WT). At 1 
hour post-induction, 116 genes were commonly upregulated in strains 3A and 3Amk relative to 
the empty vector control, while 142 genes were commonly downregulated (Figure 6A). There 
were 140 and 268 genes upregulated in strains 3A only and 3Amk only, respectively, while 176 
and 225 were downregulated. At 12 hours post-induction, a similar pattern was observed with a 
larger number of differentially expressed genes.  Please see Supplemental File S2 (Jupyter R 
notebook “IPP_transcriptomics”) for additional detail and analysis.   
We anticipated that functional enrichment of the 493 differentially expressed genes in 
strain 3Amk at t = 1 hour would provide insight into the cell’s initial response to IPP 
accumulation.  Specifically, the onset of the metabolic “pause”, which was characterized by 
reduced glucose uptake and declining ATP levels.  Enrichment analysis showed that numerous 
genes involved in RNA processing and modification were upregulated at 1 hour (Figure 6B).  
Methionine and pyrimidine ribonucleotide biosynthesis were also upregulated, along with genes 
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involved in tRNA wobble base modification, tRNA processing, and ribosome biogenesis.  DNA 
replication and repair were also uniquely upregulated in strain 3Amk, while the lexA repressor of 
genes involved in SOS response to DNA damage was downregulated (DH1’s genotype is recA1).  
These data suggest that IPP accumulation has a significant impact on nucleotide metabolism and 
DNA and RNA metabolic processes.  Intriguingly, genes involved in lipopolysaccharide (LPS) 
biosynthesis, specifically those that catalyze glycosyl transfer from nucleotide sugars, were 
significantly downregulated at 1 hour post-induction.   
The 12-hour time point was during growth recovery and declining IPP levels in strain 
3Amk.  During strain 3Amk’s recovery, 679 genes spanning multiple functional categories were 
differentially expressed.  The components of the F1 and F0 subcomplexes of ATP synthase were 
strongly upregulated in strain 3Amk at t = 12 hours.  Genes associated with purine nucleotide 
biosynthesis from 5-phospho-α-D-ribose 1-diphosphate were also identified, along with genes 
related to purine nucleoside monophosphate formation.  Also upregulated were genes involved in 
peptidoglycan metabolism and lipopolysaccharide core region biosynthesis, which was 
previously downregulated at t = 1 hour.  These data suggest that ATP synthesis and cell wall 
biosynthesis play a significant role in the growth recovery from IPP toxicity in strain 3Amk.  
Though we were primarily interested in the transcriptomic response to IPP stress, we also 
investigated common transcriptomic responses in strain 3A and 3Amk.  These genes might be 
involved in cell’s response to the metabolic burden of heterologous pathway expression.  At t = 1 
hour, genes associated with the response to heat and protein folding were upregulated in both 3A 
and 3Amk (Figure 6B).  These include the DnaK chaperone system, and chaperones involved in 
re-solubilization of aggregated proteins or folding of newly synthesized proteins.  It is likely this 
response is linked to the production of heterologous pathway proteins, which can occupy a 
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significant portion of the total proteome and comprised 35-40% of total transcript reads in strains 
3A and 3Amk.  Ribonucleoside-diphosphate reductase and its flavodoxin, responsible for 
converting ribonucleoside diphosphates to deoxyribonucleoside diphosphates (e.g., ADP to 
dADP), were also upregulated in both strains.  Unexpectedly, genes involved in many common 
stress responses were downregulated relative to DH1 WT in both 3A and 3Amk.  Phosphate 
starvation response genes were downregulated, potentially in response to the liberation of 
phosphate groups from IPP during isoprenol production.  In addition, tryptophan transport and 
biosynthesis from 5-phospho-α-D-ribose 1-diphosphate were significantly downregulated in both 
strains. At t = 12 hours, the overlap between strain 3A and 3Amk increased, perhaps indicative 
of strain 3Amk’s active recovery from IPP toxicity.  We observed functional enrichment of 
genes involved in aerobic respiration, proton and cation transport, and TCA cycle metabolism, 
all of which were upregulated relative to DH1 WT.  DNA recombination was also upregulated.  
Protein metabolism was broadly downregulated, along with cellular responses to heat and 
nutrient levels.  The numerous shared responses between strain 3A and 3Amk further underscore 
the broad metabolic impacts of heterologous pathway expression and highlight the utility of our 
experimental platform: assessment of IPP stress through a direct comparison of strain 3Amk and 
DH1 WT would yield multiple false-positives.  
 
3.7. IPP accumulation is linked to the formation of a toxic isoprenyl-ATP analog  
Our omics data suggested that IPP accumulation results in a metabolic “pause”, a 
significant reduction in the ATP pool, and dramatic changes in the expression of genes involved 
in nucleotide metabolism.  Previous work in eukaryotic cells demonstrated that IPP accumulation 
due to the inhibition of higher terpene synthesis results in the formation of the toxic isoprenyl-
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ATP analog ApppI, which is associated with apoptosis (Mönkkönen et al., 2006) (Figure 7A).  
ApppI is synthesized from AMP and IPP by aminoacyl tRNA synthetases and inhibits the 
activity of adenosine nucleotide transporter (ANT) (Mönkkönen et al., 2006).  Though there is 
no ANT homolog in E. coli, the formation of ATP analogs is associated with toxicity in a variety 
of organisms (Hong and Pedersen, 2008), and we hypothesized that their formation could 
contribute to IPP toxicity in E. coli.  
To examine the feasibility of this hypothesis we searched our LC-MS metabolomics data 
for a mass corresponding to ApppI (m/z 574).  Interestingly, not only was a mass of m/z 574 
identified, but the relative abundance of the mass closely mirrored the concentration of IPP in 
strain 3Amk (Figure 7B).  Furthermore, the relative abundance was inversely correlated to the 
intracellular concentration of ATP.  Though no standard for ApppI is commercially available, a 
standard was synthesized as described previously (Weisell et al., 2015).  To positively identify 
the presence of ApppI, we repeated our production fermentations with all three strains and took 
samples for intracellular metabolites at 3 hours post-induction where we had previously 
identified the highest concentrations of IPP (Figure 1C).  LC-MS analysis positively identified 
the mass we had previously observed as ApppI by retention time and mass spectra (Figure 7C).  
As in the previous time course, the ApppI peak area was ~10-fold greater in strain 3Amk than 
strain 3A.  No ApppI was detected in the DH1 EV control.   
 
4. Discussion 
In this work, we show that IPP toxicity is a complex stress with severe physiological 
consequences.  Elevated levels of IPP caused growth inhibition, reduced cell viability as 
measured by live/dead staining and CFU counts, and plasmid instability.  Several results 
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suggested that membrane function or integrity were compromised in the presence of IPP, 
including the observation of cell elongation, increased levels of osmoprotectants such as proline 
and betaine, and differential expression of genes involved in peptidoglycan and 
lipopolysaccharide biosynthesis.  The unexpected presence of phosphorylated intermediates in 
extracellular samples of strain 3Amk might also suggest abnormal membrane function.  IPP 
accumulation had an obvious impact on nutrient uptake: IPP was anti-correlated with amino acid 
consumption, and glucose uptake was completely shut down when IPP levels were their highest.  
Elevated IPP was also anti-correlated with ATP levels, which declined sharply during the onset 
of IPP accumulation and remained low until IPP levels were reduced.  Transcriptomics showed 
that the onset of IPP accumulation was associated with significant perturbations in nucleotide 
metabolism and the induction of DNA repair mechanisms, while recovery from IPP toxicity 
correlated with increases in ATP and cell wall biosynthesis.  Finally, it was shown that IPP 
accumulation led to the formation of ApppI, a nucleotide analog of IPP that is likely to 
contribute to IPP toxicity.    
The heterologous MVA pathway “broke” in response to IPP accumulation, underscoring 
the strong selective pressure imposed by IPP toxicity.  In our experimental system, the 
immediate response to IPP accumulation was a reduction of PMK protein levels that led to 
reduced pathway flux to IPP and implementation of an “IPP bypass”.  The exact mechanism 
behind this reduction in PMK is still unclear.  No obvious mutations were identified in the PMK 
open reading frame or ribosomal binding site (data not shown).  Suggestively, mean transcript 
levels of PMK in strain 3Amk decreased by 60% from t = 1 hour to t = 12 hours, compared to an 
increase of ~100% in strain 3A (Supplemental Figure S7).  Still, transcript levels of multiple 
pathway genes decreased from 1 to 12 hours in both strains, and only PMK protein levels in 
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strain 3Amk declined.  These results seem to imply that PMK protein is particularly unstable, or 
perhaps targeted for degradation.  A re-inoculation experiment further highlighted strain 
instability.  The “secondary” culture of strain 3Amk showed no growth inhibition and produced 
no detectable IPP or isoprenol, indicating that the heterologous pathway was no longer 
functional.  Additional work is needed to fully characterize these breakage mechanisms and 
engineer mitigations where appropriate.  These data suggest that IPP toxicity imposes a 
fundamental limit to isoprenoid pathway productivity and genetic stability.  Until mitigations are 
implemented, strategies to keep IPP levels low (Chou and Keasling, 2013) or bypass IPP 
completely (Kang et al., 2016) are particularly valuable.    
The presence of IPP in extracellular samples of strain 3Amk was unexpected.  We 
initially hypothesized that the presence of extracellular IPP was an indication of cell lysis, as a 
phosphorylated intermediate should not passively cross the cell membrane.  However, we did not 
detect other metabolites that should be strictly intracellular (e.g., nucleotides, acetyl-CoA, etc.) in 
the extracellular media as might be expected with considerable cell lysis.  While cell lysis could 
still play a role in the “export” of IPP, follow-up analysis indicated that IPP is transported, or at 
least taken-up, by the engineered E. coli DH1 used in this study (Figure 5).  Recent work in 
mammalian dendritic cells showed that ATP-binding cassette transporter A1 (ABCA1) plays a 
role in extracellular IPP release (Castella et al., 2017).  Several ABC transporters with homology 
to ABCA1 such as MetN were upregulated in strain 3Amk, though we are unable to link any of 
these transporters with IPP efflux with the current data set (Supplemental File S2, Jupyter R 
notebook “IPP_transcriptomics”).  If confirmed, the presence of as-yet uncharacterized IPP 
transporters in E. coli could be relevant to the study of isoprenoid biosynthesis in plants, which 
contain a plastid-localized MEP pathway and a cytosolic MVA pathway for isoprenoid 
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biosynthesis.  Researchers studying “cross-talk” between these two pathways have identified IPP 
as a likely candidate for exchange between the plastid and cytosol, however no plastid-
membrane components capable of prenyl diphosphate transport have been identified (Lipko and 
Swiezewska, 2016).  IP has also been highlighted as a potential “exchangeable” intermediate 
between the plastid and cytosol (Sun et al., 2016), and here, too, we see evidence of transport in 
E. coli.  Extracellular IP was detected in strain 3Amk and the comparably “healthy” strain 3A, 
where IP levels approached 100 µM (Figure 4B, Supplemental Figure S6).  Numerous 
transporter families were upregulated in strain 3A or 3Amk, though it is again unclear what 
impact these transporters might have on IP or IPP transport.  Still, these data suggest that prenyl 
mono- and diphosphate transport might be more common than previously believed.  Further 
investigation into the nature of this transport could yield targets for metabolic engineering and 
aid efforts to identify IPP/IP transporters in plants and other hosts.    
MVA pathway metabolites were not the only phosphorylated intermediates detected in 
the extracellular media.  In strain 3A, the MEP pathway intermediate MEcPP accumulated to 
~12 µM in the growth media, while intracellular levels approached 40 mM, a concentration that 
eclipsed every MVA pathway intermediate except for mevalonate.  Extracellular MEcPP was 
previously observed in E. coli with an engineered MEP pathway, where metabolite profiling 
identified MEcPP efflux as a limiting step in MEP-based isoprenoid production (Zhou et al., 
2012).  Overexpression of IspG, the enzyme downstream of MEcPP, led to increased lycopene 
production and reduced concentrations of extracellular MEcPP.  The fosmidomycin efflux pump 
Fsr was suggested to play a potential role in MEcPP export.  Though we cannot rule out other 
transporters, fsr was indeed upregulated in strain 3A by ~3.5 fold at 1 hour and ~15.5 fold at 12 
hours.  Engineering to reduce unwanted MEcPP production (e.g., IspG overexpression) could be 
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beneficial for isoprenol production or perhaps isoprenoid production in general, although further 
work is needed to determine the prevalence of this phenomenon in isoprenoid-producing E. coli.  
More broadly, the identification of elevated levels of MEcPP in a strain without MEP pathway 
engineering hints at potential interplay between the MVA and MEP pathways that warrants 
further exploration.   
The identification of the IPP-nucleotide analog ApppI in this study is, to our knowledge, 
the first evidence of its formation in prokaryotic systems.  In eukaryotes, ApppI is believed to 
result from a back reaction between IPP and AMP-amino acids catalyzed by aminoacyl tRNA 
synthetases (Mönkkönen et al., 2006).  A route of formation involving T4 RNA ligase or T4 
DNA ligase has also been proposed (Sillero et al., 2009).  Though identification of the ApppI 
formation pathway was beyond the scope of this work, the high conservation of aminoacyl tRNA 
synthetases over evolutionary time (Perona and Hadd, 2012) makes this reaction plausible in 
both eukaryotes and prokaryotes such as E. coli.  Suggestively, formation of ApppI by this 
mechanism consumes ATP in a futile cycle (Figure 7D).  Depending on the concentrations of 
ApppI that build up and the kinetics of this back reaction, this futile cycle could contribute to the 
decreased ATP pool observed in strain 3Amk.  Unfortunately, due to the difficulty in obtaining 
sufficient amounts of ApppI standard, only relative quantities of the ATP analog could be 
calculated.  In future work, a more accurate estimation of intracellular concentrations of ApppI, 
coupled with in vitro work to assess the kinetics of the back reaction, may give clearer insight 
into whether this futile cycle plays a role in the observed toxicity.  
  Nucleotide analogs are frequently used as treatments for cancer and viral diseases due to 
their bioactivity and inhibitory effect on enzymes such as DNA polymerase, ribonucleotide 
reductase, and pyrimidine nucleoside phosphorylase (Jordheim et al., 2013).  Nucleotide analogs 
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may also be incorporated into DNA, leading to DNA damage and the inhibition of cellular 
division or viral replication.  Though research on the physiological consequences of ApppI 
accumulation is still limited, preliminary evidence points to considerable bioactivity: ApppI has 
been shown to inhibit the Adenosine Nucleotide Transporter (ANT) (Mönkkönen et al., 2006) 
and ATP-gated P23X receptor (Ishchenko et al., 2017) in eukaryotes.  Inhibition of ANT has 
been directly linked to cell death and apoptosis in osteoclasts (Mönkkönen et al., 2006).  ApppI 
can also bind to the surface of F1-ATPase (Mookerjee-Basu et al., 2010), an enzyme that is 
frequently inhibited by nucleotide analogs (Hong and Pedersen, 2008).   Additional research is 
clearly necessary to determine the impact of ApppI accumulation on prokaryotic systems.  Still, 
it is suggestive that genes involved in nucleotide metabolism and DNA damage repair were 
significantly upregulated in strain 3Amk at the same time ATP levels were reduced.  These 
observations are consistent with known effects of certain nucleotide analogs and the potential 
inhibition of ATPase by ApppI, which would compound the effects of the futile cycle resulting 
from its formation (Figure 7D).   
While the detection of ApppI in this study is exciting, we were unable to probe its 
toxicity directly due to the difficulty of synthesizing sufficient quantities of the analog.      
However, if the formation of ApppI is indeed the mediator of IPP associated toxicity in E. coli, 
engineering the host to overcome this stress may prove challenging.  For example, if the back 
reaction from IPP and AMP-amino acid can be catalyzed by all aminoacyl tRNA synthetases, it 
would be a daunting task to engineer each enzyme to not promote the back reaction.  If, however, 
only a subset of aminoacyl tRNA synthetases catalyze this back reaction, the engineering 
problem will prove much more tractable.  Future in vitro studies that characterize each individual 
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aminoacyl tRNA synthetase's propensity to catalyze the formation of ApppI will hopefully guide 
rational engineering efforts to make more IPP tolerant hosts.   
 
5. Conclusion 
 In this work, we design a three-strain experimental platform to isolate the impact of IPP 
toxicity from the stress associated with heterologous pathway expression.  Using this platform, 
we assess the physiological consequences of IPP accumulation with complementary multi-omics 
data.  We show that IPP accumulation is linked to reduced cell viability, pathway “breakage” at 
PMK, reduced nutrient uptake and ATP levels, and perturbed nucleotide metabolism.  We also 
observe the extracellular accumulation of IPP and other phosphorylated intermediates, findings 
that could be relevant to the study of isoprenoid pathway “cross-talk” in other organisms.  
Finally, we show that IPP accumulation results in the formation of ApppI, a nucleotide analog of 
IPP known to be toxic to eukaryotes.  Though additional work is needed, we propose that the 
formation of this metabolite may contribute to the observed IPP toxicity phenotypes.  These data 
identify potential engineering targets for the alleviation of IPP toxicity and thus facilitate the 
construction of high-flux isoprenoid-producing strains.   
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Figure legends 
 
Figure 1.  Experimental platform to study IPP toxicity.  (A)  Isoprenol pathway reactions and 
associated heterologous genes.  7 genes were overexpressed in a plasmid-based isoprenol 
biosynthetic pathway.  The conversion of IP to isoprenol proceeds via native E. coli 
phosphatases.  In the current pathway, HMGS and HMGR are derived from Staphylococcus 
aureus (mvaS and mvaA, respectively), MK, PMK, and PMD are derived from Saccharomyces 
cerevisiae, and AtoB and NudB are derived from E. coli.  (B)  Plasmid architecture in strain 3A, 
3Amk, and DH1-EV (WT).  Each strain harbored 2 plasmids.  For strains 3A and 3Amk, plasmid 
1 (medium copy p15A ori) contained a single operon of the first 5 genes of the pathway driven 
by a lacUV5 promoter.  Plasmid 2 (high copy ColE1 ori) contained nudB and PMD driven by a 
Trc promoter.  In strain 3Amk, an additional copy of MK was placed on plasmid 2.  Strain DH1-
EV (WT) contained versions of plasmid 1 and plasmid 2 that contained no promoter and no 
heterologous pathway genes.    (C)  IPP, OD, and isoprenol levels in each strain.  The x-axis 
shows time post-induction in hours, referred to in subsequent figures as “hours” for the purpose 
of simplification.  Note that a log scale is used for OD600nm.  Error bars represent standard 
deviation of the mean (n = 3).  Note that error bars are obscured by the markers in most cases.       
  
 
Figure 2. Physiological impact of IPP accumulation.  (A)  Incidence of dead cells in strains 3A 
and 3Amk.  % dead cells in cultures of strains 3A and 3Amk were quantified using live/dead 
staining coupled with FACs.  Error bars represent standard deviation of the mean (n = 3).  (B)  
Strain 3Amk live/dead micrograph.  Representative micrograph of strain 3Amk at 6 hours post-
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induction following live/dead staining.  Note the presence of elongated cells and a staining 
phenotype consistent with compromised membrane integrity.  (C) Strain 3A live/dead 
micrograph.  Representative micrograph of strain 3A at 6 hours post-induction following 
live/dead staining.  (D) Comparison of CFUs vs. OD for strain 3A and 3Amk.  CFUs were 
recovered on LB agar for comparison with OD600 nm (dashed lines).  Note the striking decrease in 
CFUs from 0 to 6 hours post-induction for strain 3Amk, which occurred despite a >2-fold 
increase in OD.  Error bars show standard deviation of the mean (n = 3).  (E) CFUs on selective 
and non-selective media for strain 3Amk.  By 24 hours, there were fewer CFUs recovered on 
selective media (“Cm” = chloramphenicol, “Cb” = carbenicillin) than on non-selective media 
(“LB”).   The number of asterisks (*) denote varying levels of significance (see legend for 
relative p-values).  Error bars show standard deviation of the mean (n = 3).  (F)  CFUs on 
selective and non-selective media for strain 3A.  The number of asterisks (*) denote varying 
levels of significance (see legend for relative p-values).  Error bars represent standard deviation 
of the mean (n = 3). 
 
Figure 3.  PMK protein expression is attenuated in strain 3Amk in response to IPP accumulation.  
(A) Pathway proteomics.  Shotgun proteomics samples were collected over an 18-hour time 
course to assess protein expression and stability.  Concentrations are presented in relative units 
(R.U.).  PMK protein levels (*) are highlighted to show decrease at 6 hours.  Error bars represent 
standard deviation of the mean (n = 3).  See also Figure S2.   (B) Pathway metabolomics.  
Intracellular concentrations of each metabolite are shown in mM, extracellular isoprenol 
concentrations are in mg/L.  Mev-PP levels (*) are highlighted to show decrease at 6 hours.  
Error bars represent standard deviation of the mean (n = 3).  (C) IPP bypass explains continued 
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isoprenol production.  Disruption of PMK (red “X”) will still permit isoprenol production 
through an “IPP bypass” pathway catalyzed by PMD.  Isoprenol concentrations in strain 3Amk 
are shown with an adjusted scale to highlight continued production despite a decrease in PMK 
levels. 
 
Figure 4.  Aggregate metabolomics data set and representative analyses.  (A) Measured 
intracellular metabolites and relative concentrations over time.  Mean intracellular concentrations 
(n = 3) of each metabolite are shown for each time point.  Relative concentrations were 
determined by log2 transformation after adding a small constant.  See Supplemental File S1, 
Jupyter R notebook “IPP_metabolomics” for more information.  (B)  Measured extracellular 
metabolites and relative concentrations over time.  Mean extracellular concentrations (n = 3) of 
each metabolite are shown for each time point.  (C) Plot of the first 4 principal components of 
the intracellular data.  Principal components analysis was performed using log2 transformed data 
and the contributions of top four metabolites to the pair of principal components were shown as 
arrows. See Supplemental File S1, Jupyter R notebook “IPP_metabolomics” for more 
information.  (D) Plot of the first 4 principal components of the extracellular data.  (E) ATP 
concentration and energy charge is reduced in strain 3Amk.  Error bars show standard deviation 
of the mean (n = 3).  (F) Nutrient uptake is reduced during periods of IPP accumulation.  
Extracellular glucose concentrations (in mM) and extracellular valine concentrations (in µM) are 
shown.  Error bars represent standard deviation of the mean (n = 3).  
 
Figure 5. Evidence of IPP uptake in strain 3Amk.  (A) Intracellular and extracellular IPP in strain 
3Amk.  Error bars represent standard deviation of the mean (n = 3).  (B) Experimental design to 
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evaluate IPP stability.  (C)  IPP in supernatant collected at t = 6 hours. IPP is stable in filter 
sterilized (FS) and 3 kDa molecular weight cut-off (MWCO) treatments.  Error bars show 
standard deviation of the mean (n = 3).  (D)  IPP in supernatant collected at t = 15 hours. IPP is 
again stable in both treatments.  Error bars represent standard deviation of the mean (n = 3). 
 
Figure 6. Shared and distinct transcriptomic responses in 3A and 3Amk.  (A) Venn diagrams of 
significantly upregulated or downregulated genes (adjusted p-value < 0.1 and |log2 fold change| 
> 1) in strain 3A and 3Amk at 1 and 12 hours post-induction. (B) and (C) Functional enrichment 
of differentially expressed genes (adjusted p-value < 0.1) in 3A only, 3Amk only, or both 3A and 
3Amk at t = 1 hour and 12 hours, respectively. 
 
Figure 7. Accumulation of ATP analog ApppI in strain 3Amk.  (A) Chemical structures of ApppI 
and IPP. (B) A compound consistent with ApppI (m/z 574) accumulates in strain 3Amk and is 
correlated with IPP accumulation.  An anticorrelation with ATP levels is also observed.  Error 
bars represent standard deviation of the mean (n = 3).  *Putative ApppI concentrations in mM 
were calculated based on the standard curve of ATP since a reliable ApppI standard curve was 
not available for quantitation. (C) The putative ApppI peak in strain 3Amk is consistent with a 
chemically synthesized standard.  Note that while a small peak is present in strain 3A, the 
compound is not present in WT.  Chromatograms from 3 biological replicates are shown. (D) 
The formation of ApppI could result in a futile cycle that drains ATP levels.  Preliminary 
evidence suggests that ApppI binds ATPase, which could further inhibit ATP production.       
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